Immunohistochemical analysis of tumor tissues revealed that the combination treatment significantly decreased the expression of Ki-67 (proliferation marker), c-Myc, and ORC2 in both H23 and H2122SR xenografts (Fig. 6I–L). The gene discussed is MKI67; the disease is neoplasm.